Notably, we observed that SHIP2 activity is elevated in kidneys of patients with T2D receiving nonmetformin medication compared with people without diabetes and that metformin reduces the elevated activity of SHIP2 in the kidneys of patients with T2D, proposing a mechanism via which metformin acts renoprotectively. This evidence concerns the gene INPPL1 and diabetes mellitus.